<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877769</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-007</org_study_id>
    <nct_id>NCT04877769</nct_id>
  </id_info>
  <brief_title>Bronchopulmonary PK of AT-527 (R07496998)</brief_title>
  <official_title>A Phase 1, Open-label, Randomized Study in Healthy Subjects to Assess the Bronchopulmonary Pharmacokinetics, Safety and Tolerability of AT-527, a Potential Treatment for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of&#xD;
      AT-527 (R07496998)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of AT-527 in epithelial lining fluid</measure>
    <time_frame>4-5 hours after last dose and 11-12 hours after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>AT-527 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>administered twice daily (BID) for 2.5 days (5 doses in total)</description>
    <arm_group_label>AT-527 Group A</arm_group_label>
    <arm_group_label>AT-527 Group B</arm_group_label>
    <arm_group_label>AT-527 Group C</arm_group_label>
    <other_name>RO7496998</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must agree to use birth control, as required by the protocol.&#xD;
&#xD;
          -  Females must have a negative pregnancy test at Screening and prior to dosing&#xD;
&#xD;
          -  Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2&#xD;
&#xD;
          -  Willing to comply with the study requirements and to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days of dosing&#xD;
&#xD;
          -  Concomitant use of prescription medications, or systemic over-the-counter medications&#xD;
&#xD;
          -  Other clinically significant medical conditions or laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Atea Study Clinical Trials Administrator</last_name>
    <phone>888-481-1607</phone>
    <email>AteaClinicalTrials@ateapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Atea Study Site</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atea Study Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

